下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Equities Analysts Issue Forecasts for BioNTech SE's Q3 2022 Earnings (NASDAQ:BNTX)
股票分析师发布对BioNTech SE 2022年第三季度收益的预测(纳斯达克代码:BNTX)

Defense World ·  {{timeTz}}

BioNTech SE (NASDAQ:BNTX – Get Rating) – Research analysts at SVB Leerink dropped their Q3 2022 EPS estimates for BioNTech in a research report issued on Tuesday, August 9th. SVB Leerink analyst D. Graybosch now forecasts that the company will post earnings per share of $2.32 for the quarter, down from their prior forecast of $2.50. SVB Leerink currently has a "Outperform" rating and a $224.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is $34.43 per share. SVB Leerink also issued estimates for BioNTech's Q2 2023 earnings at $4.98 EPS, Q4 2023 earnings at $6.73 EPS, Q2 2024 earnings at $0.59 EPS, FY2024 earnings at $3.48 EPS, FY2025 earnings at $7.76 EPS and FY2026 earnings at $9.64 EPS.

BIONTech SE(纳斯达克代码:BNTX-GET Rating)-SVB Leerink的研究分析师在8月9日星期二发布的一份研究报告中下调了对BioNTech 2022年第三季度每股收益的预期。SVB Leerink分析师D.GrayBosch现在预测,该公司本季度每股收益将为2.32美元,低于此前预测的2.50美元。SVB Leerink目前对该股的评级为“跑赢大盘”,目标价为224.00美元。对BioNTech目前全年收益的普遍预期为每股34.43美元。SVB Leerink还发布了对BioNTech 2023年第二季度每股收益的预测为4.98美元,2023年第四季度每股收益为6.73美元,2024年第二季度每股收益为0.59美元,2024财年每股收益为3.48美元,2025财年每股收益为7.76美元,2026财年每股收益为9.64美元。

Get
到达
BioNTech
BioNTech
alerts:
警报:

A number of other equities analysts have also recently commented on BNTX. JPMorgan Chase & Co. set a $183.00 price objective on shares of BioNTech in a research report on Tuesday, May 10th. Canaccord Genuity Group reissued a "buy" rating and set a $192.00 target price on shares of BioNTech in a report on Wednesday, July 6th. Berenberg Bank set a $312.00 target price on BioNTech in a report on Tuesday. Canaccord Genuity Group lifted their target price on BioNTech from $192.00 to $200.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft set a $180.00 target price on BioNTech in a report on Friday, July 1st. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $235.62.

其他一些股票分析师最近也对BNTX发表了评论。摩根大通在5月10日周二的一份研究报告中为BioNTech的股价设定了183.00美元的目标价。Cancord Genuity集团在7月6日周三的一份报告中重新发布了“买入”评级,并为BioNTech的股票设定了192.00美元的目标价。贝伦伯格银行在周二的一份报告中为BioNTech设定了312.00美元的目标价。Cancord Genuity Group在周二的一份报告中将BioNtech的目标价从192.00美元上调至200.00美元,并给予该股“买入”评级。最后,德意志银行Aktiengesellschaft在7月1日(星期五)的一份报告中为BioNTech设定了180.00美元的目标价。六位股票研究分析师对该股的评级为持有,七位分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该股目前的共识评级为“适度买入”,共识目标价为235.62美元。

BioNTech Trading Up 2.4 %

BioNTech股价上涨2.4%

BNTX stock opened at $160.92 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.05 and a quick ratio of 4.93. The company has a fifty day moving average price of $154.62 and a two-hundred day moving average price of $157.38. BioNTech has a one year low of $117.08 and a one year high of $418.00. The stock has a market cap of $39.11 billion, a price-to-earnings ratio of 2.80 and a beta of -0.08.
BNTX股票周三开盘报160.92美元。该公司的负债权益比为0.01,流动比率为5.05,速动比率为4.93。该公司的50日移动平均价为154.62美元,200日移动平均价为157.38美元。BioNtech的一年低点为117.08美元,一年高位为418.00美元。该股市值为391.1亿美元,市盈率为2.80倍,贝塔系数为-0.08。

BioNTech (NASDAQ:BNTX – Get Rating) last released its earnings results on Monday, August 8th. The company reported $6.45 earnings per share for the quarter, missing the consensus estimate of $7.08 by ($0.63). BioNTech had a net margin of 55.13% and a return on equity of 122.24%. The firm had revenue of $3.20 billion during the quarter, compared to the consensus estimate of $4.11 billion. During the same period in the prior year, the business posted $12.98 earnings per share. BioNTech's quarterly revenue was down 39.8% compared to the same quarter last year.

生物科技(纳斯达克代码:BNTX-GET Rating)最近一次发布财报是在8月8日(星期一)。该公司公布本季度每股收益为6.45美元,低于普遍预期的7.08美元(0.63美元)。BioNTech的净利润率为55.13%,股本回报率为122.24%。该公司本季度营收为32亿美元,而市场普遍预期为41.1亿美元。去年同期,该业务公布的每股收益为12.98美元。与去年同期相比,BioNTech的季度收入下降了39.8%。

Institutional Inflows and Outflows

机构资金流入和流出

Several institutional investors have recently bought and sold shares of the business. Mackenzie Financial Corp raised its stake in BioNTech by 206.8% during the second quarter. Mackenzie Financial Corp now owns 4,753 shares of the company's stock worth $709,000 after acquiring an additional 3,204 shares in the last quarter. Boston Common Asset Management LLC raised its stake in BioNTech by 1.3% during the second quarter. Boston Common Asset Management LLC now owns 283,776 shares of the company's stock worth $42,311,000 after acquiring an additional 3,595 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp raised its stake in BioNTech by 13.0% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 250,410 shares of the company's stock worth $37,336,000 after acquiring an additional 28,810 shares in the last quarter. Pictet Asset Management SA raised its stake in BioNTech by 18.4% during the second quarter. Pictet Asset Management SA now owns 626,089 shares of the company's stock worth $93,350,000 after acquiring an additional 97,247 shares in the last quarter. Finally, Foster & Motley Inc. acquired a new position in BioNTech during the second quarter worth about $463,000. Institutional investors and hedge funds own 14.42% of the company's stock.

几家机构投资者最近买卖了该公司的股票。麦肯锡金融公司在第二季度增持了206.8%的BioNtech股份。麦肯锡金融公司(Mackenzie Financial Corp)目前持有该公司4,753股股票,价值70.9万美元,此前该公司在上个季度额外购买了3,204股票。波士顿共同资产管理有限责任公司在第二季度将其在BioNTech的持股增加了1.3%。波士顿共同资产管理公司(Boston Common Asset Management LLC)目前持有283,776股该公司股票,价值42,311,000美元,上个季度又收购了3,595股。三菱UFJ信托银行(Mitsubishi UFJ Trust&Banking Corp)第二季度增持BioNTech股份13.0%。三菱UFJ信托银行(Mitsubishi UFJ Trust&Banking Corp)目前持有250,410股该公司股票,价值37,336,000美元,此前该公司在上个季度增持了28,810股。Pictet Asset Management SA在第二季度将其在BioNTech的持股增加了18.4%。Pictet Asset Management SA现在拥有626,089股该公司股票,价值93,350,000美元,上个季度又收购了97,247股。最后,Foster&Motley Inc.在第二季度收购了BioNTech的一个新头寸,价值约46.3万美元。机构投资者和对冲基金持有该公司14.42%的股票。

About BioNTech

关于BioNTech

(Get Rating)

(获取评级)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

BioNTech SE是一家生物技术公司,开发和销售治疗癌症和其他传染病的免疫疗法。该公司正在开发FixVac候选产品,包括治疗晚期黑色素瘤的第二阶段临床试验的BNT111、治疗前列腺癌的第一阶段/第二阶段临床试验的BNT112、治疗HPV阳性头颈癌的第二阶段临床试验的BNT113、治疗三阴性乳腺癌的第一阶段临床试验的BNT114、治疗卵巢癌的第一阶段临床试验的BNT115以及治疗非小细胞肺癌的临床前阶段产品BNT116。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on BioNTech (BNTX)
  • Could Rite Aid Be an Acquisition Target, Again?
  • The How And Why of Investing in Oil Stocks
  • The How and Why of Investing in Gold Stocks
  • A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
  • Workhorse Group Is Ready To Get Back On The Horse
  • 免费获取StockNews.com关于BioNTech的研究报告(BNTX)
  • Rite Aid会再次成为收购目标吗?
  • 投资石油股票的方式和原因
  • 投资黄金股票的方式和原因
  • DraftKings,Inc.的圆底开始逆转
  • 工作马集团准备重返赛马

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.

获得《BioNTech Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioNTech和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部